In another presentation from the ESMO meeting in Madrid, Spain, Fizazi et al. presented data from the randomized CABA-DOC trial exploring patients’ preferences for either docetaxel or cabazitaxel as a first-line form of chemotherapy. … READ MORE …
Filed under: Management, Treatment | Tagged: cabazitaxel, chemotherapy, choice, docetaxel, preference, taxane | 2 Comments »
TAPS stands for “taxane acute pain syndrome”. It is a recognized side effect of treatment with taxanes like docetaxel and it is usually characterized by muscular pain (myalgia) and joint pain (arthralgia) that starts about 24 to 48 hours after taxane treatment and then lasts for up to about 7 days. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Risk, Treatment | Tagged: chemotherapy, pain, TAPS, taxane, Treatment | 9 Comments »
Drugs like docetaxel and cabazitaxel (taxanes) are among the most active forms of treatment in the management of men with metastatic, castration-resistant prostate cancer (mCRPC), but they don’t work for everyone. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Risk, Treatment | Tagged: cabazitaxel, docetaxel, expression, gene, taxane, TMPRSS2-ERG | Leave a comment »
Researchers at Weill Cornell Medical Center claim to have worked out more precisely how taxane-based chemotherapy (using drugs like paclitaxel, docetaxel, and cabazitaxel) actually works … with particular reference to how it works in prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: chemotherapy, docetaxel, taxane | Leave a comment »
Long-term follow-up data have just been published from two studies designed to provide preliminary information on the potential use of very aggressive forms of treatment in men with high-risk categories of prostate cancer. … READ MORE …
Filed under: Management, Treatment | Tagged: aggressive, androgen deprivation, docetaxel, hormone, paclitaxel, radiation, taxane, therapy | 7 Comments »
Our second report today deals with:
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Prevention, Risk, Uncategorized | Tagged: apolipoprotein, chemotherapy, isoflavone, prognosis, PSA "half-life", sensitization, soy, taxane, VEBSA, vitamin E analog | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 